Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

The pathology of the thymus in myasthenia gravis; a study of 35 cases.

CASTLEMAN B, NORRIS EH.

Medicine (Baltimore). 1949 Feb;28(1):27-58. No abstract available.

PMID:
18115401
2.

Clinical and serological study of myasthenia gravis in HuBei Province, China.

Zhang X, Yang M, Xu J, Zhang M, Lang B, Wang W, Vincent A.

J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):386-90. Epub 2006 Nov 6.

3.

The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice.

Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL.

Clin Exp Immunol. 2006 Nov;146(2):294-302.

4.

Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia.

Kaminski HJ, Kusner LL, Richmonds C, Medof ME, Lin F.

Exp Neurol. 2006 Dec;202(2):287-93. Epub 2006 Jul 20.

PMID:
16859686
5.

C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1.

Fosbrink M, Niculescu F, Rus V, Shin ML, Rus H.

J Biol Chem. 2006 Jul 14;281(28):19009-18. Epub 2006 May 2.

6.

A central role for central tolerance.

Kyewski B, Klein L.

Annu Rev Immunol. 2006;24:571-606. Review.

PMID:
16551260
7.

The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis.

Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tallaksen C, Berrih-Aknin S.

Blood. 2006 Jul 15;108(2):432-40. Epub 2006 Mar 16.

8.

MuSK Ab described in seropositive MG sera found to be Ab to alkaline phosphatase.

Ohta K, Shigemoto K, Kubo S, Maruyama N, Abe Y, Ueda N, Fujinami A, Ohta M.

Neurology. 2005 Dec 27;65(12):1988. No abstract available.

PMID:
16380629
9.

A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.

Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R.

Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227-32. Epub 2005 May 3.

10.

Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation.

Spreadbury I, Kishore U, Beeson D, Vincent A.

J Neuroimmunol. 2005 May;162(1-2):149-56.

PMID:
15833370
11.

Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.

Leite MI, Ströbel P, Jones M, Micklem K, Moritz R, Gold R, Niks EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A.

Ann Neurol. 2005 Mar;57(3):444-8.

PMID:
15732104
12.

Thymus changes in anti-MuSK-positive and -negative myasthenia gravis.

Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, Bartoccioni E, Evoli A.

Neurology. 2005 Feb 8;64(3):536-8.

PMID:
15699390
13.

Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation.

van Beek J, van Meurs M, 't Hart BA, Brok HP, Neal JW, Chatagner A, Harris CL, Omidvar N, Morgan BP, Laman JD, Gasque P.

J Immunol. 2005 Feb 15;174(4):2353-65.

14.

Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects.

Davies CS, Harris CL, Morgan BP.

Immunology. 2005 Feb;114(2):280-6.

15.

Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.

Kaminski HJ, Li Z, Richmonds C, Lin F, Medof ME.

Exp Neurol. 2004 Oct;189(2):333-42.

PMID:
15380483
16.

Expression of a functional C5a receptor in regenerating hepatocytes and its involvement in a proliferative signaling pathway in rat.

Daveau M, Benard M, Scotte M, Schouft MT, Hiron M, Francois A, Salier JP, Fontaine M.

J Immunol. 2004 Sep 1;173(5):3418-24.

17.

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.

McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A.

Ann Neurol. 2004 Apr;55(4):580-4.

PMID:
15048899
18.

Scenarios for autoimmunization of T and B cells in myasthenia gravis.

Shiono H, Roxanis I, Zhang W, Sims GP, Meager A, Jacobson LW, Liu JL, Matthews I, Wong YL, Bonifati M, Micklem K, Stott DI, Todd JA, Beeson D, Vincent A, Willcox N.

Ann N Y Acad Sci. 2003 Sep;998:237-56.

PMID:
14592881
19.

Clinical aspects of MuSK antibody positive seronegative MG.

Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A.

Neurology. 2003 Jun 24;60(12):1978-80.

PMID:
12821744
20.

Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E.

Brain. 2003 Oct;126(Pt 10):2304-11. Epub 2003 Jun 23.

PMID:
12821509

Supplemental Content

Support Center